Abstract Background: To determine the burden of Rheumatoid Arthritis (RA) on patients' work productivity and health related quality of life (HRQoL), and examine the influence of several exposure variables; to analyze the progression of RA over 1 year and its impact on work productivity and HRQoL. Methods: International multicenter prospective survey including patients in 18 centers in Argentina, Brazil, Colombia and Mexico with diagnosis of RA and aged between 21-55 years. The following standard questionnaires were completed at baseline and throughout a 1-year follow-up: WPAI:RA, WALS, WLQ-25, EQ-5D-3 L and SF-36. Clinical and demographic variables were also collected through interview. Results: The study enrolled 290 patients on baseline visit. Overall mean scores at baseline visit were: WPAI:RA (presenteeism) = 29.5% (SD = 28.8%); WPAI:RA (absenteeism) = 9.0% (SD = 23.2%); WPAI:RA (absenteeism and presenteeism) = 8.6% (SD = 22.6%); WALS = 9.0 (SD = 6.1); WLQ-25 = 7.0% (SD = 5.1%); SF-36 Physical Scale = 39.1 (SD = 10.3) and Mental Scale = 45.4 (SD = 11.3); EQ-5D-3 L VAS = 69.8 (SD = 20.4) and EQ-5D-3 L index = 0.67 (SD = 0.23). Higher educational levels were associated with better results in WLQ-25, while previous orthopedic surgeries reduced absenteeism results of WPAI:RA and work limitations in WLQ-25. Higher disease duration was associated with decreased HRQoL. Intensification of disease activity was associated with decreased work productivity and HRQoL, except in WLQ-25. In the longitudinal analysis, worsening in disease activity was associated with a decrease in both work productivity and HRQoL. Conclusions: RA patients are dealing with workplace disabilities and limitations and loss in HRQoL, and multiple factors seems to be associated with this. Worsening of disease activity further decreased work productivity and HRQoL, stressing the importance of disease tight control.

Se presenta el caso de una paciente de 23 años de edad, con diagnóstico de síndrome de anticuerpos antifosfolípidos, con un cuadro típico de trombosis venosa profunda recurrente y pérdidas fetales, en presencia de anticoagulante lúpico y anticuerpos anticardiolipina positivos. En el transcurso de su enfermedad presenta manifestaciones hemorrágicas, no explicadas por el uso de anticoagulantes orales. Los estudios de hematología permitieron documentar una disminución de los factores IX y VIII, con evidencia de inhibidor específico del factor IX. La deficiencia de factores de la coagulación mejoró gracias al uso de esteroides y ciclofosfamida. (Acta Med Colomb 2011; 36: 196-199)

We report the case of a 23-year-old female patient with an antiphospholipid syndrome characterized by recurrent deep venous thromboses and fetal losses, with positive lupus anticoagulant and anticardiolipin antibodies. During the course of the disease she had hemorrhagic manifestations not attributable to oral anticoagulants. Hematological analyses documented reduced levels of factors IX and VIII, with evidence of a specific inhibitor of factor IX. The deficiency of clotting factors improved with steroids and cyclophosphamide. (Acta Med Colomb 2011; 36: 196-199)

Introducción: la esclerodermia es una alteración autoinmune caracterizada por induración y engrosamiento de la piel. Durante el curso de la enfermedad los pacientes pueden padecer síntomas de afectación musculoesquelética que incluyen artralgias, artritis, pérdida de función articular y discapacidad consecuente. Objetivos: se estudió la relación de las manifestaciones osteo-articulares clínicas y radiológicas con los anticuerpos anti-péptido citrulinado en una cohorte de pacientes con esclerodermia. Materiales y métodos: se evaluó la historia clínica de pacientes con esclerodermia buscando datos con características de la enfermedad, afectación de órgano blanco y síntomas osteo-articulares. A todos los pacientes se les realizó anticuerpos anti-péptido citrulinado de tercera generación y se les tomó radiografía de manos y pies. Resultados: se incluyeron en forma consecutiva 123 pacientes y se analizaron los datos de 100 pacientes. Ochenta y cuatro pacientes con esclerodermia limitada y 16 con esclerodermia difusa. El promedio de edad fue de 55,5 años y la mediana del tiempo de diagnóstico correspondió a 6,9 años. Catorce pacientes presentaron anticuerpos anti-péptido citrulinado positivos (14%), 4 pacientes con esclerodermia difusa y 9 pacientes con esclerodermia limitada. Dieciocho pacientes (18%) presentaron el factor reumatoide IgM positivo y no se observó relación entre la afectación de órgano blanco con los anticuerpos. El 72% de los pacientes presentaron síntomas osteo-articulares, 17 de ellos presentaron artralgias (23,6%). La combinación de artralgias y artritis se observó en 25 (34,7%) de los pacientes. Artralgias, artritis y contracturas en 10 (13,9%) pacientes. Dos pacientes presentaron artritis (2,8%), 3 contracturas (4,2%) y 5 calcinosis (6,9%). Analizando la asociación entre los anticuerpos antiCCP y la afectación clínica articular, no se encontró asociación estadísticamente significativa (p= 0,095). En el análisis radiológico se observó: En las manos con mayor frecuencia resorción ósea u osteolisis (72%). También se observó calcinosis (54%), aumento de tejidos blandos (49%) y contracturas en flexión (31%). En los pies se observó con mayor frecuencia resorción falángica u osteolisis (13%). Además calcinosis (10%), disminución del espacio articular (6%). Se evidenció una asociación de calcinosis con los antiCCP positivos. Conclusión: los hallazgos articulares fueron frecuentes en esta cohorte de pacientes con esclerodermia. La prevalencia de los anticuerpos antiCCP y factor reumatoide fueron de alrededor del 15%. Se observó más alteraciones radiológicas en las manos que los pies probablemente por factores mecánicos. Se observó una asociación de calcinosis en las manos con los antiCCP.

Introduction: scleroderma is an autoimmune disease characterized by induration and thickening of skin. Patients may suffer from musculoskeletal symptoms which include arthralgias, arthritis, loss of articular function and disability. Objectives: we sought to assess any association between radiographic features, osteoarticular manifestations, and anti-CCP antibodies in a cohort of scleroderma patients. Materials and methods: we evaluated the clinical features of patients searching for demographic characteristics, organ system involvement and osteoarticular symptoms. The presence of anti-CCP IgG was evaluated in all patients. Standard radiographs of hands and feet were taken and analyzed. Results: one hundred twenty three consecutive patients were included and 100 patients were analyzed in the present study. Eighty four patients had limited scleroderma and 16 patients had diffuse scleroderma. The mean age was 55.5 years and the median time of diagnostic was 6.9 years. Fourteen patients were positive for presence of anti-CCP (14%), 4 patient for diffuse form and 9 patients for limited form. Eighteen patients were positive for IgM rheumatoid factor test (18%). It was not seen an association between organ involvement and antibodies. Seventy two percent of patients showed osteoarticular symptoms, 17 of them had arthralgias (23.6%), 25 had arthralgias and arthritis (34.7%), and 10 had arhtralgias, arthritis and contractures (13.9%). Two patients showed arthritis (2.8%), three contractures (4.2%) and 5 calcinosis (6.9%). There was no association between the presence of anti-CCP antibodies and osteoarticular manifestations (p= 0.095). Radiographic features seen on hands were osteolysis (72%), calcinosis (54%), increasing of soft tissues (49%) and flexion contractures (31%). On feet was seen osteolysis (13%), calcinosis (10%) and decreasing of articular space (6%). There was association between calcinosis and anti-CCP antibodies. Conclusion: the articular findings were frequently seen in this scleroderma cohort. Prevalence of anti-CCP antibodies and rheumatoid factor was around 15% positive. Hands showed more alterations than feet, probably for mechanistic factors. It was seen an association between hand calcinosis and anti-CCP antibodies.